Sign up
Pharma Capital

Dyadic International posts higher revenue from R&D, new sublicensing collaborations

Dyadic International Inc (NASDAQ:DYAI) Chief Accounting Officer Ping Rawson says the Florida-based biotech reported a 119% increase in first-quarter research and development revenue compared to the same period a year ago.

Chief Scientific Officer Ronen Tchelet explained the value of its recently formed, exciting sub-licensing agreements with both Alphazyme and Serum Institute of India.

 

View full DYAI profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.